Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have ...

Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and ...

Cosmo Fowler, M.D., from Emory University in Atlanta, and colleagues examined data from the TriNetX U.S. Collaborative Network to examine whether OSA modifies outcomes in patients with T2DM receiving ...

Patients with T2D and overweight/obesity starting GLP-1 therapy may experience a small but statistically significant increase ...

Among nearly 10,000 GLP-1 receptor agonist prescriptions given at a single health system, 60.1% were filled, reported Ameet ...

Researchers have identified that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely used to control type ...

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is increasing in clinical trials to treat overlapping ...

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

NEW YORK CITY — Dermatologists should be thinking about offering hormonally-active weight loss drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as part of routine care for psoriasis ...

A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs. An alarming 40% of orders for glucagon-like peptide-1 ...

Glycemic, weight, cardiometabolic outcomes improved for children and teens with obesity, prediabetes, or T2D. (HealthDay News) — In children and adolescents with type 2 diabetes (T2D) or obesity, ...

"Our findings suggest that GLP-1 RAs [receptor agonists] confer substantial cardioprotective and kidney-protective benefits to patients with SLE and LN with comorbid T2D [type 2 diabetes], who are ...